Sandoz Infringed Amgen's Psoriasis Drug Patents, Court Says
By Hailey Konnath (September 20, 2021, 11:32 PM EDT) -- A New Jersey federal judge on Monday found that Sandoz and Zydus Pharmaceuticals infringed several of Amgen's patents for its blockbuster plaque psoriasis medication Otezla, entering judgment in favor of Amgen on a trio of patents.
U.S. District Judge Michael A. Shipp upheld the validity of four patents covering Otezla and found that Sandoz Inc. and Zydus Pharmaceuticals had each infringed three of the patents. At the same time, the judge found that Sandoz and Zydus hadn't infringed other patents covering methods of treating psoriasis with apremilast, Otezla's active ingredient, according to a specific dosing schedule.
Amgen had accused the generic-drug...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!